They seem to have a decent niche carved out. Miss Cathie may be right for once?
m
Jim Cramer says, correctly imo, this is a time to buy stocks with earnings which CDNA does not have. This is a Cathie Wood stock (with massive potential) and could easily go under $10
m
Department of Justice (DOJ) has issued a civil investigative demand (CID) requesting documents for an investigation over certain business conduct related to its kidney testing and phlebotomy services. In addition, the company said it received a subpoena from the SEC in connection with a probe on similar matters and certain accounting and public reporting practices. Another unnamed state regulatory agency has also made an information request. “The Company does not believe that the CID, the SEC subpoena or the state regulatory agency information request raise any issues regarding the safety or efficacy of any of the Company's products or services and are cooperating fully with the investigations,” CareDx added.
J
Simply... Worth repeating from previous post...Great Conference...AlloSure > 2 Billion Dollar market > 65% margin...GLTA...
AlloSure Efficient Commercial Launch Concentrated Call Points 265 Tertiary Care Centers 100 centers account for 80% of kidney transplants Broad reimbursement at Launch 80% of patients covered by Medicare Leverage Existing AlloMap Infrastructure Core laboratory, reimbursement, G&A infrastructure in place Leverage Existing Commercial Channel Commercial presence in major transplant centers Field Team and Marketing already in place Significant Pre-Launch Commercialization Activity Strong foundation for rapid adoption and growth *Medicare Rate Source: Company estimates 18,000 Kidney Transplants 265 Centers (100 centers = 80% transplants) Year 1: 7 AlloSure tests, 4/year > $2 Bn >> opportunity (in launch) $2,840 >65% AlloMap provides commercial platform Transplant per Year 2,600 Heart Transplants Targets 130 Centers (50 centers = 70% transplants) Testing Frequency Year 1: 6-8 tests, 2-4/year Addressable Market $100 M Revenue > $30 M (current run-rate) Reimbursement/Test* $2,840 → $3,240 Gross Margin ≈65%
J
Just the facts>>>>>>>>>>2 billion...No competition in a 2 billion dollar market...During the third quarter, the CareDx team achieved several important milestones with respect to AlloSure. As a reminder, AlloSure measures donor-derived cell-free DNA to detect active organ rejection. AlloSure represents CareDx entry into the large kidney transplant surveillance diagnostic market. In the U.S. alone, there are more than 18,000 kidney transplants annually and an estimated 200,000 patients currently living with a transplanted kidney. There are approximately 10x the number of patients living with kidney transplants compared to those living with heart transplants, translating into an addressable market opportunity of greater than $2 billion annually
R
I've seen these scenarios before! There will be a NEWS from the company management that all the documents are in place rightly and this will pop to the old price minus a couple of percent.... OLD STORY!
Y
CareDx reached a 52 Week low at 24.87
E
time to buy more share
t
CDNA price target raised by Craig-Hallum from 35 to 40. Hopefully this link will post here from The Street dot Com. You'll see the article under "From our Partners" on the page...
View detailed financial information, real-time news, videos, quotes and analysis on CareDx Inc. (NASDAQ:CDNA). Explore commentary on CareDx Inc. and hear what the experts at TheStreet are saying about CDNA
View detailed financial information, real-time news, videos, quotes and analysis on CareDx Inc. (NASDAQ:CDNA). Explore commentary on CareDx Inc. and hear what the experts at TheStreet are saying about CDNA
www.thestreet.com
R
Medical Services is currently in the top 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1
A
Now we know why...
Funds and institutions ENERGIING and taking new positions...
Fred Alger Management Inc 1,238,351 4.30 New 0.04
Perceptive Advisors LLC 1,040,676 3.61 New 0.25
Gagnon Advisors, LLC 952,222 3.32 26,929.36 5.14
Wellington Management Company LLP 928,200 3.22 New 0
Stonepine Capital Management Llc 920,000 3.19 New 4.05
Park West Asset Management LLC 809,793 2.81 New 0.27
Emerald Mutual Fund Advisers Trust 500,000 1.73 New 0.15
Midroc Invest AB, Co. 476,462 9.18 31.96 0
FastPartner AB 424,184 8.17 31.97 0
EAM Investors 373,896 1.30 New 0.36
Vanguard Group Inc 371,610 2.38 117.63 0
Next Century Growth Investors LLC 286,969 2.72 57.71 0.72
In addition, the company said it received a subpoena from the SEC in connection with a probe on similar matters and certain accounting and public reporting practices. Another unnamed state regulatory agency has also made an information request.
“The Company does not believe that the CID, the SEC subpoena or the state regulatory agency information request raise any issues regarding the safety or efficacy of any of the Company's products or services and are cooperating fully with the investigations,” CareDx added.
AlloSure
Efficient Commercial Launch
Concentrated Call Points
265 Tertiary Care Centers
100 centers account for 80% of kidney transplants
Broad reimbursement at Launch
80% of patients covered by Medicare
Leverage Existing AlloMap Infrastructure
Core laboratory, reimbursement, G&A infrastructure in place
Leverage Existing Commercial Channel
Commercial presence in major transplant centers
Field Team and Marketing already in place
Significant Pre-Launch Commercialization Activity
Strong foundation for rapid adoption and growth
*Medicare Rate
Source: Company estimates
18,000 Kidney Transplants
265 Centers
(100 centers = 80% transplants)
Year 1: 7 AlloSure tests, 4/year
> $2 Bn
>> opportunity (in launch)
$2,840
>65%
AlloMap provides commercial platform
Transplant per Year 2,600 Heart Transplants
Targets 130 Centers
(50 centers = 70% transplants)
Testing Frequency Year 1: 6-8 tests, 2-4/year
Addressable Market $100 M
Revenue > $30 M (current run-rate)
Reimbursement/Test* $2,840 → $3,240
Gross Margin ≈65%
OLD STORY!
https://www.thestreet.com/quote/CDNA.html
Funds and institutions ENERGIING and taking new positions...
Fred Alger Management Inc 1,238,351 4.30 New 0.04
Perceptive Advisors LLC 1,040,676 3.61 New 0.25
Gagnon Advisors, LLC 952,222 3.32 26,929.36 5.14
Wellington Management Company LLP 928,200 3.22 New 0
Stonepine Capital Management Llc 920,000 3.19 New 4.05
Park West Asset Management LLC 809,793 2.81 New 0.27
Emerald Mutual Fund Advisers Trust 500,000 1.73 New 0.15
Midroc Invest AB, Co. 476,462 9.18 31.96 0
FastPartner AB 424,184 8.17 31.97 0
EAM Investors 373,896 1.30 New 0.36
Vanguard Group Inc 371,610 2.38 117.63 0
Next Century Growth Investors LLC 286,969 2.72 57.71 0.72
Merckle International GmbH 226,915 4.18 23.41 0
Private Wealth Partners, LLC 201,000 1.51 85.53 0.59
Wexford Capital LP 200,000 0.69 New 0.13
Granite Point Capital Management LP 190,000 0.66 New 0.14
Royce & Associates, LLC 180,300 3.38 22.74 0.05
Awm Investment Company Inc 175,000 0.61 New 0.25
Friess Associates LLC 146,416 0.51 New 0.09
Jacob Asset Management Of New York LLC 117,000 0.41 New 3.57
Alger Small Cap Focus A 452,458 4.67 50.62 1.15
Jacob Small Cap Growth Investor 75,667 0.26 New 3.61
Alger Small Cap Growth I-2 68,698 0.58 68.76 0.49
Royce Micro Cap Trust 56,000 0.19 New 0.11
Vanguard Extended Market Idx Inv 55,300 0.99 23.86 0
Alger Small Cap Growth B 43,540 0.37 69.17 0.49
Jacob Micro Cap Growth Institutional 41,333 0.14 New 3.49
AMG Managers Emerging Opps Svc 29,132 0.46 28.41 0.45
BNY Mellon EB DL Mkt Completion 10,600 0.04 1,872.79 0
Alger Small Cap Growth Institutional I 5,604 0.38 5.38 0.32
BNY Mellon Market Completion Fund UC1 630 0 111.31 0
Wells Fargo Dow Jones Target 2050 R6 22 0 3.91 0
Wells Fargo Dow Jones Target 2040 A 7 0 0.70 0
Wells Fargo Dow Jones Target 2055 R6 6 0 5.56 0
Wells Fargo Dow Jones Target 2045 R6 3 0 0.87 0
Wells Fargo Dow Jones Target Today A 2 0 3.85 0
Wells Fargo Dow Jones Target 2060 A 2 0 7.14 0
https://www.ptcommunity.com/wire/sahm-adrangis-kerrisdale-capital-issues-negative-report-caredx-inc-and-announces-conference
Funds and institutions ENERGIING and taking new positions...
Fred Alger Management Inc 1,238,351 4.30 New 0.04
Perceptive Advisors LLC 1,040,676 3.61 New 0.25
Gagnon Advisors, LLC 952,222 3.32 26,929.36 5.14
Wellington Management Company LLP 928,200 3.22 New 0
Stonepine Capital Management Llc 920,000 3.19 New 4.05
Park West Asset Management LLC 809,793 2.81 New 0.27
Emerald Mutual Fund Advisers Trust 500,000 1.73 New 0.15
Midroc Invest AB, Co. 476,462 9.18 31.96 0
FastPartner AB 424,184 8.17 31.97 0
EAM Investors 373,896 1.30 New 0.36
Vanguard Group Inc 371,610 2.38 117.63 0
Next Century Growth Investors LLC 286,969 2.72 57.71 0.72
Merckle International GmbH 226,915 4.18 23.41 0
Private Wealth Partners, LLC 201,000 1.51 85.53 0.59
Wexford Capital LP 200,000 0.69 New 0.13
Granite Point Capital Management LP 190,000 0.66 New 0.14
Royce & Associates, LLC 180,300 3.38 22.74 0.05
Awm Investment Company Inc 175,000 0.61 New 0.25
Friess Associates LLC 146,416 0.51 New 0.09
Jacob Asset Management Of New York LLC 117,000 0.41 New 3.57
Alger Small Cap Focus A 452,458 4.67 50.62 1.15
Jacob Small Cap Growth Investor 75,667 0.26 New 3.61
Alger Small Cap Growth I-2 68,698 0.58 68.76 0.49
Royce Micro Cap Trust 56,000 0.19 New 0.11
Vanguard Extended Market Idx Inv 55,300 0.99 23.86 0
Alger Small Cap Growth B 43,540 0.37 69.17 0.49
Jacob Micro Cap Growth Institutional 41,333 0.14 New 3.49
AMG Managers Emerging Opps Svc 29,132 0.46 28.41 0.45
BNY Mellon EB DL Mkt Completion 10,600 0.04 1,872.79 0
Alger Small Cap Growth Institutional I 5,604 0.38 5.38 0.32
BNY Mellon Market Completion Fund UC1 630 0 111.31 0
Wells Fargo Dow Jones Target 2050 R6 22 0 3.91 0
Wells Fargo Dow Jones Target 2040 A 7 0 0.70 0
Wells Fargo Dow Jones Target 2055 R6 6 0 5.56 0
Wells Fargo Dow Jones Target 2045 R6 3 0 0.87 0
Wells Fargo Dow Jones Target Today A 2 0 3.85 0
Wells Fargo Dow Jones Target 2060 A 2 0 7.14 0